Acepodia, Inc.
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in Phase 1 clinical trial; ACE183 … Read more
Acepodia, Inc. (6976) - Total Liabilities
Latest total liabilities as of June 2024: NT$405.55 Million TWD
Based on the latest financial reports, Acepodia, Inc. (6976) has total liabilities worth NT$405.55 Million TWD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Acepodia, Inc. - Total Liabilities Trend (2020–2023)
This chart illustrates how Acepodia, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Acepodia, Inc. Competitors by Total Liabilities
The table below lists competitors of Acepodia, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Young Optics Inc
TW:3504
|
Taiwan | NT$1.44 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥74.29 Million |
|
Diana Shipping Inc.
NYSE:DSX
|
USA | $684.13 Million |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
China | CN¥139.62 Million |
|
Caswell Inc
TW:6416
|
Taiwan | NT$1.92 Billion |
Liability Composition Analysis (2020–2023)
This chart breaks down Acepodia, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 60.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acepodia, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acepodia, Inc. (2020–2023)
The table below shows the annual total liabilities of Acepodia, Inc. from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | NT$384.47 Million | -94.41% |
| 2022-12-31 | NT$6.88 Billion | +28.41% |
| 2021-12-31 | NT$5.36 Billion | +456.39% |
| 2020-12-31 | NT$963.47 Million | -- |